Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steffen Bauer

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Clinical Pharmacology|May 29, 2007
Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritisDavid Czock, Franz Maximilian Rasche, Alexander Carius, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 12, 2004
The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantationAnne-Kathrin Pieper, Franziska Buhle, Steffen Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2002
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypesRolf Kaiser, Orhan Sezer, Anja Papies, et al.
Clinical Pharmacology and Therapeutics|October 31, 2003
Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokineticsIsabella Gashaw, Julia Kirchheiner, Mark Goldammer, et al.
Planta Medica|April 28, 2005
No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extractGerhard Arold, Frank Donath, Agathe Maurer, et al.
European Journal of Clinical Pharmacology|June 8, 2006
Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarinMyong-Jin Kim, Anne N Nafziger, Angela D M Kashuba, et al.
Journal of Clinical Psychopharmacology|January 19, 2002
Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum )Andreas Johne, Jürgen Schmider, Jürgen Brockmöller, et al.
Clinical Pharmacology and Therapeutics|October 8, 2004
Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamicsJulia Kirchheiner, Claudia Heesch, Steffen Bauer, et al.
Transplantation|February 24, 2007
Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomesKlemens Budde, Petra Glander, Bernhard K Krämer, et al.
Pharmacogenetics and Genomics|September 7, 2010
Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulationsMarkus Wehland, Steffen Bauer, Susanne Brakemeier, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Clinical Pharmacology|May 29, 2007
Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritisDavid Czock, Franz Maximilian Rasche, Alexander Carius, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 12, 2004
The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantationAnne-Kathrin Pieper, Franziska Buhle, Steffen Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2002
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypesRolf Kaiser, Orhan Sezer, Anja Papies, et al.
Clinical Pharmacology and Therapeutics|October 31, 2003
Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokineticsIsabella Gashaw, Julia Kirchheiner, Mark Goldammer, et al.
Planta Medica|April 28, 2005
No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extractGerhard Arold, Frank Donath, Agathe Maurer, et al.
European Journal of Clinical Pharmacology|June 8, 2006
Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarinMyong-Jin Kim, Anne N Nafziger, Angela D M Kashuba, et al.
Journal of Clinical Psychopharmacology|January 19, 2002
Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum )Andreas Johne, Jürgen Schmider, Jürgen Brockmöller, et al.
Clinical Pharmacology and Therapeutics|October 8, 2004
Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamicsJulia Kirchheiner, Claudia Heesch, Steffen Bauer, et al.
Transplantation|February 24, 2007
Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomesKlemens Budde, Petra Glander, Bernhard K Krämer, et al.
Pharmacogenetics and Genomics|September 7, 2010
Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulationsMarkus Wehland, Steffen Bauer, Susanne Brakemeier, et al.
Pageof 5